Radiologisches Institut / Gyn. Radiologie University Breast Cancer Cent Franken diologische Mammadiagnostik oder Genetik oder Beide Universitätsklinikum Erlangen Universitäts-Brustzentrum Franken Radiologisches Institut der FAU Erlangen- Nürnberg Direktor: Prof. Dr. med. M. Uder Gynäkologische Radiologie R. Schulz-Wendtland
107
Embed
Radiologisches Institut / Gyn. Radiologie University Breast Cancer Center Franken Radiologische Mammadiagnostik oder Genetik oder Beides? Universitätsklinikum.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Radiologisches Institut / Gyn. Radiologie
UniversityBreast Cancer CenterFranken
Radiologische Mammadiagnostik oder Genetik oder Beides?
Universitätsklinikum ErlangenUniversitäts-Brustzentrum FrankenRadiologisches Institut der FAU Erlangen-NürnbergDirektor: Prof. Dr. med. M. UderGynäkologische Radiologie
Dark field imaging in a series of surgery specimens of breast cancer patients (BD14)
Peter A. Fasching (1), Jens Rieger (2), Florian Bayer (2), Florian Horn (2), Georg Pelzer (2), Thilo Michel (2), Andre Ritter (2), Thomas Weber (2), Julius Emons (1), Michael Uder (3), Evelyn Wenkel (3), David Wachter (4), Iris Polifka (4), Claudia Rauh (1), Felix Heindl (1), Marcus Radicke (5), Arndt Hartmann (4), Matthias W. Beckmann (1), Rüdiger Schulz-Wendtland (3), Gisela Anton (2)
1) Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen- Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany2) Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany3) Institute for Diagnostic Radiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany4) Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany5) Siemens AG; Healthcare Sector; Clinical Products Division, X-Ray Products; H CP XP R&D TEC PI, Erlangen, Germany
Radiologisches Institut / Gyn. Radiologie
Radiologisches Institut / Gyn. Radiologie
ECAP: vertikaler Talbot-Lau Interferometer mit 25 keV Energie
Mikroskopische Gitteraufnahmen: Institut für Mikrostrukturtechnik, IMT, KIT
Gitter-Schacht-
Verhältnis, IMT, KIT
Radiologisches Institut / Gyn. Radiologie
Messung
Phasenkontrast Mastektomiepräparat mit invasivem Mammakarzinom cT3 cN0
Dietzel et al. 2013, Li et al. 2013, Baltzer et al. 2012, Tofts 2010
Mammakarzinom
Radiologisches Institut / Gyn. Radiologie
OBJECTIVES: This study aimed to assess the diagnostic performance of integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) of the breast for lesion detection and local tumor staging of patients with primary breast cancer in comparison to PET/computed tomography (CT) and MRI.MATERIALS AND METHODS: The study was approved by the local institutional review board. Forty-nine patients with biopsy-proven invasive breast cancer were prospectively enrolled in our study. All patients underwent a PET/CT, and subsequently, a contrast-enhanced PET/MRI of the breast after written informed consent was obtained before each examination. Two radiologists independently evaluated the corresponding data sets (PET/CT, PET/MRI, and MRI) and were instructed to identify primary tumors lesions as well as multifocal/multicentric and bilateral disease. Furthermore, the occurrence of lymph node metastases was assessed, and the T-stage for each patient was determined. Histopathological verification of the local tumor extent and the axillary lymph node status was available for 30 of 49 and 48 of 49 patients, respectively. For the remaining patients, a consensus characterization was performed for the determination of the T-stage and nodal status, taking into account the results of clinical staging, PET/CT, and PET/MRI examinations. Statistical analysis was performed to test for differences in diagnostic performance between the different imaging procedures. P values less than 0.05 were considered to be statistically significant.RESULTS: Positron emission tomography/MRI and MRI correctly identified 47 (96%) of the 49 patients with primary breast cancer, whereas PET/CT enabled detection of 46 (94%) of 49 breast cancer patients and missed a synchronous carcinoma in the contralateral breast in 1 patient. In a lesion-by-lesion analysis, no significant differences could be obtained between the 3 imaging procedures for the identification of primary breast cancer lesions (P > 0.05). Positron emission tomography/MRI and MRI allowed for a correct identification of multifocal/multicentric disease in 3 additional patients if compared with PET/CT. For the definition of the correct T-stage, PET/MRI and MRI showed identical results and were correct in significantly more cases than PET/CT (PET/MRI and MRI, 82%; PET/CT, 68%; P < 0.05). Furthermore, the calculated sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for the detection of nodal positive patients (n = 18) were 78%, 94%, 88%, 88%, and 88% for PET/CT; 67%, 87%, 75%, 82%, and 80% for MRI; and 78%, 90%, 82%, 88%, and 86% for PET/MRI, respectively. Differences between the imaging modalities were not statistically significant (P > 0.05).CONCLUSIONS: Integrated PET/MRI does not provide diagnostic advantages for local tumor staging of breast cancer patients in comparison to MRI alone. Positron emission tomography/MRI and MRI enable an improved determination of the local tumor extent in comparison to PET/CT, whereas all 3 imaging modalities offer a comparable diagnostic performance for the identification of axillary disease.
Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T, Forsting M, Quick HH, Umutlu L, Kinner S
CONCLUSIONS: Integrated PET/MRI does not provide diagnostic advantages for local tumor staging of breast cancer patients in comparison to MRI alone. Positron emission tomography/MRI and MRI enable an improved determination of the local tumor extent in comparison to PET/CT,
whereas all 3 imaging modalities offer a comparable diagnostic performance for the identification of axillary disease.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Breast Tumors at 3 and 7 T: A Comparison.Gruber, S., Pinker, K., Baltzer, P., Helbich, T. et al. Invest Radiol. 49: 354 – 362 (2014)
Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron tomography magnetic resonance imaging.Pinker, K., Baltzer, P., Gruber, S., Helbich, T. et al.Clin Cancer Res. 20: 3540 – 3549 (2014)
Radiologisches Institut / Gyn. Radiologie
Radiologisches Institut / Gyn. Radiologie
Mammadiagnostik
molekulare / genetische Bildgebung
Radiologisches Institut / Gyn. Radiologie
Problem: The Dense Breast
Radiologisches Institut / Gyn. Radiologie
UniversityBreast Cancer CenterFranken
David Geffen School of MedicineDep. Hem/OncHead: Dennis Slamon, MD, PhDUCLAUCLA
Veränderung der mammographischen Dichte und deren Assoziation mit anderen Risikofaktoren für das Mammakarzinom
Peter A. Fasching1, 4, Christian R. Loehberg1, Katharina Heusinger1, Sebastian M. Jud1, Lothar Haeberle1, Alexander Hein1, Claudia Rauh1, Mayada R. Bani1, Michael P. Lux1, Michael G. Schrauder1, Cosima Helbig2, Roland Grolik2, Boris Adamietz3, Matthias W. Beckmann1, Ruediger Schulz-Wendtland3
1 University Breast Center Franconia, Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitaetsstrasse 21–23, 91054 Erlangen, Germany2 Medizinisches Zentrum für Informations- und Kommunikationstechnik, Erlangen University Hospital, Krankenhausstraße 12, 91054 Erlangen, Germany3 Institute for Diagnostic Radiology, University Hospital Erlangen, Erlangen University Hospital, Universitaetsstrasse 21-23, 91054 Erlangen, Germany4 University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, Los Angeles, USA
Besetzung•Ethan Hawke: Vincent Freeman•Uma Thurman: Irene Cassini•Jude Law: Jerome Eugene Morrow•Gore Vidal: Director Josef•Alan Arkin: Detective Hugo•Xander Berkeley: Dr. Lamar•Jayne Brook: Marie Freeman•William Lee Scott: jugendlicher Anton Freeman•Loren Dean: erwachsener Anton Freeman•Ernest Borgnine: Caesar•Tony Shalhoub: „German“ (Genom-Makler)•Elias Koteas: Antonio Freeman
Gattaca ist ein US-amerikanischer Science-Fiction-Film aus dem Jahr 1997.
Die technische Entwicklung ist so weit fortgeschritten, dass man das menschliche Erbgut wie ein Buch lesen und Veranlagungen für alle erdenklichen Krankheiten, geistige und physische Fähigkeiten, sowie die durchschnittliche Lebenserwartung daraus ermitteln kann.
In dieser Gesellschaft haben nur mittels Gentechnik künstlich ausgewählte Menschen die Möglichkeit eines beruflichen Fortkommens. Bei der Geburt des Protagonisten Vincent Freeman liest die Krankenschwester nach einem Bluttest vor, dass Vincent eine genetische Disposition für ein schwaches Herz und damit eine niedrige Lebenserwartung habe.